Teva Pharmaceutical Industries (NYSE:TEVA) Stock Price Expected to Rise, JPMorgan Chase & Co. Analyst Says

Teva Pharmaceutical Industries (NYSE:TEVA) had its price objective upped by research analysts at JPMorgan Chase & Co. from $28.00 to $35.00 in a research report issued to clients and investors on Tuesday,Benzinga reports. The firm presently has an “overweight” rating on the stock. JPMorgan Chase & Co.‘s target price points to a potential upside of 16.46% from the company’s current price.

Other analysts have also issued research reports about the stock. Wall Street Zen lowered shares of Teva Pharmaceutical Industries from a “strong-buy” rating to a “buy” rating in a research report on Saturday, December 13th. The Goldman Sachs Group raised their target price on Teva Pharmaceutical Industries from $28.00 to $31.00 and gave the company a “buy” rating in a research report on Monday, December 8th. UBS Group lifted their price target on Teva Pharmaceutical Industries from $23.00 to $26.00 and gave the company a “buy” rating in a research note on Wednesday, September 24th. Scotiabank started coverage on Teva Pharmaceutical Industries in a research report on Friday, December 5th. They set a “sector outperform” rating and a $35.00 price target on the stock. Finally, Barclays started coverage on Teva Pharmaceutical Industries in a research report on Tuesday, December 9th. They issued an “overweight” rating and a $35.00 price objective for the company. Three research analysts have rated the stock with a Strong Buy rating, six have given a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat, Teva Pharmaceutical Industries has an average rating of “Buy” and an average target price of $31.13.

Teva Pharmaceutical Industries Stock Down 0.2%

Shares of TEVA stock opened at $30.05 on Tuesday. Teva Pharmaceutical Industries has a twelve month low of $12.47 and a twelve month high of $30.44. The stock has a market cap of $34.47 billion, a P/E ratio of 50.09, a P/E/G ratio of 1.79 and a beta of 0.67. The stock has a 50 day moving average of $24.03 and a 200 day moving average of $19.88. The company has a current ratio of 1.11, a quick ratio of 0.82 and a debt-to-equity ratio of 2.31.

Insider Activity at Teva Pharmaceutical Industries

In related news, VP Richard Daniell sold 115,468 shares of the stock in a transaction on Tuesday, December 9th. The stock was sold at an average price of $28.68, for a total value of $3,311,622.24. Following the completion of the transaction, the vice president directly owned 48,384 shares of the company’s stock, valued at approximately $1,387,653.12. This represents a 70.47% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Mark Sabag sold 216,892 shares of the company’s stock in a transaction on Tuesday, December 9th. The stock was sold at an average price of $28.73, for a total transaction of $6,231,307.16. Following the sale, the insider directly owned 52,828 shares of the company’s stock, valued at $1,517,748.44. The trade was a 80.41% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last ninety days, insiders sold 532,360 shares of company stock valued at $14,364,929. 0.49% of the stock is owned by insiders.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in the stock. Bourgeon Capital Management LLC boosted its holdings in Teva Pharmaceutical Industries by 100.7% in the second quarter. Bourgeon Capital Management LLC now owns 723,974 shares of the company’s stock valued at $12,134,000 after purchasing an additional 363,252 shares in the last quarter. Amundi lifted its position in shares of Teva Pharmaceutical Industries by 18.5% during the 1st quarter. Amundi now owns 678,758 shares of the company’s stock worth $10,080,000 after buying an additional 105,846 shares during the last quarter. IFM Investors Pty Ltd boosted its holdings in shares of Teva Pharmaceutical Industries by 9.4% in the 2nd quarter. IFM Investors Pty Ltd now owns 226,534 shares of the company’s stock valued at $3,797,000 after buying an additional 19,447 shares in the last quarter. Vontobel Holding Ltd. boosted its holdings in shares of Teva Pharmaceutical Industries by 5.5% in the 2nd quarter. Vontobel Holding Ltd. now owns 719,676 shares of the company’s stock valued at $12,062,000 after buying an additional 37,455 shares in the last quarter. Finally, Jump Financial LLC grew its position in shares of Teva Pharmaceutical Industries by 172.1% in the 1st quarter. Jump Financial LLC now owns 1,325,526 shares of the company’s stock valued at $20,373,000 after buying an additional 838,423 shares during the last quarter. 54.05% of the stock is currently owned by institutional investors and hedge funds.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.